We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Biosynth’s Peptide Division Successfully Completed GMP Inspection in Lelystad

The Biosynth logo
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Biosynth announces that its site in Lelystad, The Netherlands, successfully passed the recent GMP inspection by the Inspectie Gezondheidszorg en Jeugd (IGJ) on January 25, 2023. The scope of the inspection was the Quality Management System of the site.


The inspection, carried out by the IGJ confirmed the site to be compliant with the principles and guidelines of Good Manufacturing Practices (GMP) and no major or critical observations were issued. At the closing meeting, the inspectors stated that the site is working at or above the average level of API manufacturers. They were highly satisfied with what they had seen and complimented Biosynth on its GMP system, inspection organization and the knowledge and commitment of its team members.


Ehab Alramahy, Head of the Peptide Division, said on the inspection's outcome “We are very proud of the results achieved during this inspection. I am delighted that the IGJ inspectors reported no major or critical observations, which clearly shows the commitment of our entire team to quality and patient safety. This is another important milestone for our site in Lelystad and the Peptide Division overall, as it confirms our ability to support our customers throughout the entire lifecycle - from research to commercial supply of peptides.”


Hans de Backer, Head of Peptides Operations, added “It is a great confirmation that our customer-focus and emphasis on timely delivery goes hand in hand with complying to the highest engineering, manufacturing and quality standards for the supply of peptides. Our stronghold in small- & medium scale NCE’s and patient-centered approaches means we are continually improving and expanding the range of projects on which we work. ”